5 results
The primary objective is to assess the efficacy of nemolizumab (CD14152) compared to placebo in subjects >= 18 years of age with prurigo nodularis (PN) after a 16-week treatment period.
Study IM011-127 is a Phase 2 randomized, double-blind, placebo-controlled, multicenter clinical study designed to assess the safety and tolerability, efficacy and biomarker response of BMS-986165 12 mg BID in subjects with moderate to severe…
The scientific rationale for the study is summarized above and further detailed in Section 3 and the Investigator Brochure (IB). This Phase 2 randomized, double-blind clinical trial is designed to assess the safety and efficacy of BMS-986165 in…
The primary objective is to assess the long-term safety of nemolizumab (CD14152) insubjects with prurigo nodularis (PN).The secondary objective is to assess the long-term efficacy of nemolizumab (CD14152)in subjects with PN
Safety: To assess the safety and tolerability of BMS-986165 in LNEfficacy: Efficacy: To evaluate the efficacy of BMS 986165 compared with placebo with regard to proteinuria SecondaryEfficacy - To evaluate the efficacy of BMS-986165 with regard to…